Medicare Advantage - Clinical Criteria Updates Notification March 2021
Please note, this communication applies to Healthy Blue + Medicare℠ (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).
On March 25, 2021, and April 8, 2021, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Blue Cross NC. These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, email druglist@ingenio-rx.com.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other members of your practice and office staff.
Note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
| EFFECTIVE DATE | DOCUMENT NUMBER | CLINICAL CRITERIA TITLE | NEW OR REVISED |
|---|---|---|---|
| August 30, 2021 | ING-CC-0195* | Abecma (idecabtagene vicleucel) | New |
| August 30, 2021 | ING-CC-0191* | Pepaxto (melphalan flufenamide; melflufen) | New |
| August 30, 2021 | ING-CC-0192* | Cosela (trilaciclib) | New |
| August 30, 2021 | ING-CC-0193* | Evkeeza (evinacumab) | New |
| August 30, 2021 | ING-CC-0194* | Cabenuva (cabotegravir extended-release; rilpivirine extended-release) Injection | New |
| August 30, 2021 | ING-CC-0125 | Opdivo (nivolumab) | Revised |
| August 30, 2021 | ING-CC-0064 | Interleukin-1 Inhibitors | Revised |
| August 30, 2021 | ING-CC-0159* | Scenesse (afamelanotide) | Revised |
| August 30, 2021 | ING-CC-0151 | Yescarta (axicabtagene ciloleucel) | Revised |
| August 30, 2021 | ING-CC-0145* | Libtayo (cemiplimab-rwlc) | Revised |
| August 30, 2021 | ING-CC-0130* | Imfinzi (durvalumab) | Revised |
| August 30, 2021 | ING-CC-0127 | Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) | Revised |
| August 30, 2021 | ING-CC-0075* | Rituximab Agents for Non-Oncologic Indications | Revised |
For more information, visit our Providers page.
BNCCARE-0139-21 May 2021 518931MUPENMUB
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.